“AI for Impact” lives up to its name
Entrepreneurship class MAS.664 launches businesses with a global reach.
Entrepreneurship class MAS.664 launches businesses with a global reach.
MIT researchers employ machine learning to find powerful peptides that could improve a gene therapy drug for Duchenne muscular dystrophy.
Diagnostic nanoparticles could be used to monitor tumor recurrence after treatment or to perform routine cancer screenings.
The sensor technology could also be used to create clothing that detects a variety of pathogens and other threats.
Former naval petty officer Manuel Morales now develops imaging applications to detect cardiac dysfunction in young patients.
MIT instructors honored for creating multidimensional, multidisciplinary online courses that help learners everywhere address real-world problems.
Nearly 1,400 joined the AI for Health Care Equity Conference that explored new AI technologies as a platform for change.
A machine learning model developed jointly by Janssen and MIT data scientists played a key role in the clinical trial process for the Johnson & Johnson Covid-19 vaccine.
Alumni-founded Multiply Labs uses an automated manufacturing platform to produce advanced treatments at scale.
Kytopen is speeding up both discovery and delivery of engineered cell therapies with its transformative Flowfect platforms.
A leader in thermodynamics, heat transfer, cryopreservation of biomaterials, and energy conversion, Cravalho shaped thermodynamic and biomedical education at MIT.
Regina Barzilay, Fotini Christia, and Collin Stultz describe how artificial intelligence and machine learning can support fairness, personalization, and inclusiveness in health care.
Associate Professor Thomas Heldt finds inspiration where fundamental physical principles intersect with human health.
Kano Therapeutics was one of eight finalists to pitch at the virtual competition.
The award recognizes Weinberg’s pioneering achievements in the field of cancer biology.